Trastuzumab Plus Vinorelbine May Be an Effective Alternative for HER2-Positive Breast Cancer
the Cancer Therapy Advisor take:
According to a new study published in the journal Current Oncology, trastuzumab and vinorelbine is an effective alternative to standard taxane-based chemotherapy for patients with early stage or locally advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Researchers at Jewish General Hospital in Montreal, Quebec, Canada, sought to investigate through a retrospective analysis whether trastuzumab plus vinorelbine is a viable alternative to a taxane plus an anthracycline. Some patients refuse to this standard backbone of chemotherapy regimens for patients with HER2-positive breast cancer because of its common adverse effect of alopecia. In addition, some patients may have a contraindication to receive either of those drugs.
For the study, researchers identified 46 patients with a mean age of 64 years who received trastuzumab plus vinorelbine beetween 2003 and 2010. Most patients received the combination therapy weekly for 6 months, followed by trastuzumab alone for 6 months. Results showed a median 5-year overall survival rate of 94% and a median 5-year cancer-specific survival rate of 98%.
One patient died as a result of febrile neutropenia-induced sepsis. The most common grade 3 or 4 adverse effects included neutropenia, febrile neutropenia, fatigue, and anemia.
Trastuzumab and vinorelbine an effective alternative to standard chemo.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer